← Definium Therapeutics, Inc. (DFTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Definium Therapeutics, Inc. (DFTX)
Medicinal Chemicals & Botanical Products · market cap $5.1B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Definium Therapeutics (DFTX), formerly MindMed, is a New York-based clinical-stage biotech developing psychoplastogenic drugs, led by MM120 (LSD D-Tartrate) in Phase 3 for Generalized Anxiety Disorder and DT120 in Phase 3 for Major Depressive Disorder. The company carries a $4.76B market cap with $262.5M in cash (~18.5 months runway) and no revenue, burning approximately $118M in R&D annually. The nearest near-term event is a Q2 2026 earnings release on July 30.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 3 · DT120imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MM-120 (LSD D-Tartrate) | Phase 2 | Anxiety Generalized |
| MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder |
| DT120 | Phase 3 | Major Depressive Disorder |
Price & technical context
3-month
-14.9%
6-month
+82.5%
12-month
+218.9%
52-wk range
$10.68–$48.45
vs 50-day MA
-8.8%
vs 200-day MA
+37.8%
Realized vol
72.6%
Max drawdown
-50.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DFTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.